ClinicalTrials.gg
Active, not recruitingNCT05799287Updated Dec 16, 2025

A Study of Telitacicept for IgA Nephropathy (TELIGAN)

A Phase 3 interventional study of Telitacicept and Placebo in Primary IgA Nephropathy, sponsored by RemeGen Co., Ltd.. Active, not recruiting at 101 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
318
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.

Enrollment
18th of 109
318 · median 84
Started
2023
with 10 others
Phase 3
22 of 127
9 open now
Primary completion
2026-06
later than 15 of 72 live
Registered
59th of 127
by date

Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 18th largest by enrollment of the 109 interventional ones that give a count, is one of 11 that started in 2023, is one of 22 in phase 3, reaches primary completion later than 15 of the 72 other live ones, and was the 59th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Glomerulonephritis, IGA with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with renin-angiotensin system(RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).

Read the detailed description

This study consists of a 5-week screening period, a double-blind treatment period divided into phase A and phase B. Eligible subjects will be randomly assigned in a 1:1 ratio to receive either Telitacicept 240mg or placebo. Subjects will be given subcutaneous injection(SC) Telitacicept or placebo once a week for a total of 39 doses in phase A and once every 2 weeks for a total of 32 doses in phase B.

Primary endpoint of phase A will be measured at week 39. Primary endpoint of phase B will be measured at week 104.

03

Conditions studied

  • Primary IgA Nephropathy

Keywords

  • Autoimmune Diseases
  • Immune System Diseases
  • IgA Nephropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary provided;
  2. Male or female aged ≥ 18 years old;
  3. IgA nephropathy confirmed by pathological ;
  4. During the screening period, UPCR ≥ 0.8 g/g or 24-hour urine protein ≥ 1.0 g/day based on 24-hour urine collection at Visit 1 and/or Visit 2 and at Visit 3;
  5. ≥ 30 mL/min per 1.73 m\^2 (using the CKD-EPI);
  6. Have been on a treatment regimen including ACEI/ARB for 12 weeks and on a stable use of ACEI/ARB medication at the maximum tolerated dose/maximum allowable dose within 4 weeks prior to randomization. Subjects who use both ACEIs and ARBs will be excluded.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with abnormal laboratory tests, including but not limited to the following:

    1. White blood cell count \< 1.5×109/L
    2. Neutrophils \< 1.0×109/L
    3. \< 85.0 g/L
    4. count \< 80.0×109/L
    5. Total >2×
    6. >3×ULN
    7. AST>3×ULN
    8. Alkaline phosphatase>2×ULN
    9. Creatine kinase>5×ULN
    10. IgA\<10 mg/dL; or IgG≤400mg/dL;
  2. Patients with secondary IgA nephropathy, including but not limited to: Henoch-Schonlein purpura, ankylosing spondylitis, systemic lupus erythematosus, etc.;
  3. Patients with other types of glomerular disease such as crescentic glomerulonephritis, minimal change nephropathy with IgA deposition;;
  4. Renal transplant;
  5. Patients with cirrhosis, as assessed by the investigator;
  6. Patients who experienced any of the following cardiovascular and cerebrovascular events within 24 weeks prior to randomization: myocardial infarction, unstable angina, ventricular arrhythmia, Class II or higher heart failure, stroke, etc.;
  7. Sitting position SBP>140 mmHg or DBP>90 mmHg for at least once at 2 visits during the screening period;
  8. Patients with poorly controlled type 1 and type 2 diabetes ( A1c[HbA1c] > 8% or 64mmol/mol);
  9. Treatment with within 12 weeks prior to randomization, including but not limited to cyclophosphamide, azathioprine, mycophenolate, leflunomide, tacrolimus, cyclosporine, Tripterygium wilfordii;
  10. Treatment with anti-CD20 therapy (for example, Rituximb Injection) within 24 weeks prior to randomization;
  11. Received systemic treatment within 12 weeks prior to randomization, excluding the followings: ① received systemic treatment with prednisolone ≤ 0.5mg/kg or equivalent glucocorticoid for non- IgA nephropathy for no more than 3 courses (≤ 2 weeks per course) in the past 52 weeks; ② topical administration or nasal inhalation;
  12. Had hospitalization or intravenous anti-infective therapy for active infection within 4 weeks prior to randomization;
  13. Patients with active tuberculosis;
  14. : patients with active or latent hepatitis B (potive HBcAb and HBV-DNA); According to the test results of hepatitis B five items, subjects with positive HBsAg will be excluded; subjects who are HBsAg-negative but HBcAb-positive, whether HBsAb is positive or negative, should be tested for HBV-DNA: if HBV-DNA is positive, patients should be excluded; if HBV-DNA is negative, patients can participate in the trial, and subjects are advised to take oral entecavir for prophylactic antiviral therapy during the trial;
  15. Patients with ;
  16. Patients with infection;
  17. Patients with within the past 5 years, except for treated cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, colon polyps, or cervical cancer in situ;
  18. Pregnant women, lactating women, and subjects with childbearing plans during the trial;
  19. Allergic to biological products of human origin;
  20. Participated in any clinical trial within 4 weeks or within 5 times the half-life of the drug participating (whichever is longer) prior to randomization;
  21. Received within 4 weeks prior to randomization;
  22. Drug or alcohol abuse/dependence within 52 weeks prior to randomization;
  23. Other circumstances that, in the opinion of the investigator, are not suitable for participation in this study.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
318 participants (actual)

Study arms

  • Experimental
    Telitacicept

    Subjects will be given Telitacicept 240 mg SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.

    Biological: Telitacicept

  • Placebo comparator
    Placebo

    Subjects will be given placebo SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.

    Drug: Placebo

Interventions

  • BiologicalTelitacicept

    Subcutaneous injection

    Also known as: RC18

  • DrugPlacebo

    Placebo to Telitacicept

06

What researchers measure

Primary outcomes

  1. Change from baseline in urine protein creatinine ratio (UPCR)

    Based on a 24-hour urine collections.

    Time frame: 39 weeks

  2. Annualized estimated glomerular filtration rate (eGFR) slope

    eGFR is calculated using the CKD-EPI formula.

    Time frame: 104 weeks

Secondary outcomes

  1. Proportion of patients with a 30% decrease in estimated glomerular filtration rate (eGFR) compared with baseline

    eGFR is calculated using the CKD-EPI formula.

    Time frame: 39 weeks

  2. Time to 30% reduction from baseline in eGFR

    eGFR is calculated using the CKD-EPI formula and confirmed by a second sample collection and calculation after at least 4 weeks.

    Time frame: up to 104 weeks

  3. Proportion of patients with a 40% decrease in estimated glomerular filtration rate (eGFR) compared with baseline

    eGFR is calculated using the CKD-EPI formula and confirmed by a second sample collection and calculation after at least 4 weeks.

    Time frame: up to 104 weeks

  4. Proportion of patients received rescue treatment.

    patients using systemic immunosuppressive medications, glucocorticoids (GCSs), etc.

    Time frame: up to 104 weeks

  5. Incidence and severity of adverse events

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: up to 104 weeks

  6. Change from baseline in urine protein creatinine ratio (UPCR)

    Based on 24-hour urine collections.

    Time frame: 52 weeks,78 weeks,104 weeks

  7. Change from baseline in estimated glomerular filtration rate (eGFR)

    eGFR is calculated using the CKD-EPI formula.

    Time frame: 39 weeks, 52 weeks,78 weeks,104 weeks

  8. Change from baseline in UACR in urine albumin-to-creatinine ratio (UACR)

    Based on 24-hour urine collections.

    Time frame: 39 weeks, 52 weeks,78 weeks,104 weeks

  9. Time to composite endpoint event

    The composite endpoint event is defined as initiation of maintenance renal dialysis (for at least 1 month), eGFR \<15 mL/min/1.73 m\^2, renal transplant, or death due to renal failure. eGFR is calculated using the CKD-EPI formula (CKD-EPI).

    Time frame: up to 104 weeks

  10. Proportion of patients achieving urine protein creatinine ratio (UPCR) < 0.8 g/g

    UPCR is calculated based on 24-hour urine collections;

    Time frame: 39 weeks, 52 weeks,78 weeks,104 weeks

  11. Annualized estimated glomerular filtration rate (eGFR) slope

    eGFR is calculated using the CKD-EPI formula.

    Time frame: 52 weeks

Other outcomes

  1. Change from baseline in 24-hour urine protein

    based on 24-hour urine collections

    Time frame: 39 weeks

07

Study locations

101 sites

Showing the first 100 of 101 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lv J, Liu L, Wang W, Wang X, Zuraw Q, Perkovic V, Fang J, Zhang H; TELIGAN Investigators. Telitacicept for IgA Nephropathy - Interim Analysis of a Phase 3 Trial. N Engl J Med. 2026 May 14;394(19):1916-1924. doi: 10.1056/NEJMoa2514415. PubMed 42127391 ↗
  • Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. PubMed 38299639 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2026, 38 months after the start.

Of 26 phase 3 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 70. This study's planned 38 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2023
First posted
Apr 5, 2023
StartActual
Apr 28, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05799287
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Apr 28, 2023
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Dec 16, 2025

Study contacts

Jicheng Lv, M.D.
principal investigator · Peking University First Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion